EUROPEAN PRECISION MEDICINE 2017: NOW AND BEYOND
What is about (short explanation):
Precision approach to medicine includes an individual’s genetic profile to guide decisions made in regard to the prevention, better diagnoses, earlier interventions, more-efficient drug therapies, customized treatment plans. Precision medicine provides a genomic blueprint to determine each person’s unique disease susceptibility, define preventive measures and enable targeted therapies in order to promote overall wellness.
KEY PRACTICAL POINTS OF THE CONFERENCE:
– The present and future of Precision Medicine in Europe
– Development and Implementation of Precision Medicine in Europe
– Opportunities to improve Healthcare
– New scientific knowledge, tools, methods and technologies
– Novel approaches to go above and beyond oncology
– Data Standardization
– Financing and Costs
– Commercialization of Precision Medicine
– Benefits for the Pharmaceutical Industry
– Ethical questions
To get assistance with booking a room and arranging your flight tickets please contact: Daryna Kosse
Tel.: +420 777 672 154
E-mail address: firstname.lastname@example.org
Thomas is a MD, serial entrepreneur. His current venture InnVentis focuses on the convergence of multi-omics technologies Big DATA/machine learning and real-world clinical data to enable PRECISION MEDICINE. Besides InnVentis, Thomas is an associate at deep innovation GmbH, a boutique incubator/consultancy headed by the fmr. Head Group R&D Vodafone with a focus on the creation of new, disruptive products and services from converging technologies. Before joining deep innovation, he headed a drug discovery company as CEO/CSO with a focus on inflammatory and metabolic diseases. Aside from his work in biomedicine he developed a novel concept for value creation in research intensive industries; i.e. Symbiotic Innovation. With regard to this project Thomas is an associate at the GLORAD Research Center for Global R&D Management St. Gallen/Shanghai.
Dr. Dragan Primorac is a pediatrician, forensic expert and geneticist. He serves as an adjunct professor at Eberly College of Science, The Pennsylvania State University, and Henry C. Lee College of Criminal Justice and Forensic Sciences, University of New Haven, in the United States and as professor at Medical Schools in Split and Osijek. In October of 2016.he was appointed as a visiting professor at the College of Medicine and Forensics, Xi’an Jiaotong University, People’s Republic of China. In addition, he is member of the International Consortium for Personalized Medicine Executive Committee (IC PerMEd). Currently, he serves as the Chair of the International Affairs Committee of the American Academy of Forensic Sciences. Dr. Primorac is the founder of the Specialty Hospital for Orthopedics, Neurology and Physical Medicine and Rehabilitation “St. Catherine” in Croatia, cofounder of Department of Forensic Sciences at the University of Split, Croatia as well as cofounder of the Regiomed Medical School, Germany. He has particular interest in personalized and regenerative medicine. His work was published in most cited journals including Science and Nature. Dr. Primorac is a pioneer in the application of DNA analysis for identification of bodies in mass graves and the founder of forensic DNA analysis in the region. Currently, he is a team leader of the Croatian partner in the international consortium within EU FP7 project entitled “Multi-dimensional OMICS approach to stratification of patients with low back pain”. In November of 2015 he was elected to lead the State competitiveness cluster in personalized medicine. From 2003 to 2009 he served as Minister of Science, Education and Sports, Republic of Croatia. As the Minister of Science, Education and Sports, Dr. Primorac launched a series of successful reforms in primary, secondary and tertiary education as well as in science, technology and sports that significantly improved the system.
Professor of Personalized Healthcare, Radboudumc; Chair of Biomarker Platform, EATRIS Alain van Gool is a professor of Personalized Healthcare at Radboud University Medical Center and an applied biomarker scientist at Netherlands Institute for Applied Scientific Research (TNO), with a strong passion in the application of biomarkers in translational medicine and personalized healthcare. His professional background since 1991 is a mix of academia, pharmaceutical industry, applied research institutes, university medical centers. He has been leading technology-based biomarker laboratories, cross-functional expert teams, therapeutic project teams and public-private consortia, many of which were focused on the discovery, development and implementation of translational biomarkers in a variety of therapeutic areas. While working in Europe, USA and Asia, he and his teams contributed to over 200 projects in various phases of biomarker R&D. His technical expertise resides most strongly in molecular profiling (various Omics approaches), analytical biomarker development, and applications in translational scientific research. Alain is a strong believer of open innovation networks and in his roles he has been collaborating with pharmaceutical, biotechnological, nutriceutical and diagnostic industries, SMEs, biobanks, clinicians, technology providers and information specialists to translate basic research to applied science through public-private partnerships. With that background, he currently heads the Radboudumc center for proteomics, glycomics & metabolomics, coordinates the Radboudumc Technology Centers, is Scientific Lead Technologies of DTL (the Dutch Techcenter for Life Sciences) and is chair Biomarker Platform of EATRIS (the European infrastructure for Translational Medicine) and is co-initiator of Health-RI (the Netherlands Personalized Medicine and Health Research Infrastructure), thus contributing to the organization and coordination of local, national and European technology infrastructures. Complementing his daily work, he enjoys contributing to several scientific advisory boards of start-up entrepreneurs, multinational companies, diagnostic organizations and conference organizers, and is part of several editorial boards of scientific journals.
Fabrizio Conicella has more than 20 years of experience managing organizations and R&D and technology transfer projects. In 1999 he became a Project Manager and Business Developer of Bioindustry Park Silvano Fumero. Since 2001 he was working as a Director of Business development and International Projects and a manager of bioPmed innovation cluster. He is now a General Manager of Bioindustry Park. Since 2011 he has been working as a contract professor both at Università di Torino and Università Piemonte Orientale in business planning, innovation management and technology transfer. He was also a President of Ephoran-MIS, a company specializing in imaging services, and he is now a member of the managing board of KITE association, member of the managing board of 2I3T, the incubator of Università di Torino, member of the managing board of APSTI – Italia Association of Science Parks, member of “Science-Industry” committee of Genopole (F) and an executive vice president of bioPmed cluster association. In the last years he has been a member of Associazione Italia start-up managing board, Assobiotec managing board and Eurotransbio Advisory Board. He has been also appointed as a member of different boards, working groups, evaluator of initiatives, projects and business plans by private and public national and international organizations.
Ph.D., Laboratory for Advanced Genomics at RBI, Rudjer Boskovic Institute Oliver Vugrek graduated in Biology at the Albert Einstein University of Ulm in 1992, and researched for a PhD at the Max Planck Institute for Cellbiology, presenting his thesis in November 1995 at the Karl Ruprechts University of Heidelberg, Germany. In 1996 he was granted a 2-year postdoctoral fellowship at the Australian National University in Canberra. After his postdoc term he was employed as assistant at the RuđerBošković Institute (RBI) in 1999. From 2012 to 2015 he was appointed Head of the Department of Molecular Medicine. He is highly familiar with recombinant DNA technology, and new technologies such as microarrays, and next-generation sequencing. Throughout his research he participated in the discovery of a new metabolic disease in human, S-Adenosylhomocysteine hydrolase (SAHH) deficiency. A major achievement so far is leading FP7 project InnoMol, the largest project ever conducted in Croatia in Natural Sciences thus helping to introduce new technologies and valuable infrastructure in several life science departments at RBI. Subsequently, he has assembled a State-of-the-Art operational Next-Generation-Sequencing facility bringing genomics research at RBI to a new level. At present moment he is leading the Laboratory for Advanced Genomics at RBI.
Jonathan Sheldon, Ph.D., is Global Vice President Healthcare and responsible for Oracle’s healthcare business globally within the Health Sciences Global Business Unit which includes solutions in the areas of precision medicine, population health and convergence with Life Sciences. Previously, Dr. Sheldon has held positions of both Chief Scientific Officer and Chief Technology Officer in software companies serving both life science and healthcare sectors where he has lead the company overall strategic direction. Prior to the software industry, Dr. Sheldon was Head of Bioinformatics for five years at Roche (UK) Pharmaceuticals. Dr Sheldon has being an invited speaker at over a 100 international conferences and served on various advisory groups and boards including as a Director of the tranSMART Foundation. Most recently, Dr Sheldon was appointed to serve as a Director on the Board of DIA Dr. Sheldon holds a Ph.D. in Molecular Biology/Biochemistry from the University of Cambridge
After Gianni D’Errico graduated cum laude at University Federico II in Napoli and obtained his post graduate master’s degree in project management at SIOI in Rome, he started working in Brussels as R&D project developer and then in Maribor, where he got acquainted with R&D programs and innovative projects in Life Sciences. In Slovenia he cooperated with the University of Maribor, providing lectures to PhD students on IP issues within R&D international projects. Since September 2015 he has been working at the Regional Foundation for Biomedical Research (a strategic agency specialized in financing highly scientific projects in Life Sciences), where he is in charge of the European strategy, programs and projects with the aim to create synergies between Lombardy and other European regions’ R&D&I policies. He is member of the IC-PERMED Executive Committee, main facilitator of the ESTHER (Emerging and Strategic Technologies for Healthcare) Interregional cooperation group, and he has been implementing the participation of the Lombardy Region to TRANSCAN 2 and PERMED ERA-NET. He is in charge of regional innovation policies for AHA and of the implementation of gender guidelines among Research Funding and Research Performing Organizations
Päivi Östling obtained her PhD thesis at the Turku Centre for Biotechnology in 2006, and did her postdoctoral training at the Medical Biotechnology, Technical Research Centre of Finland (VTT) in 2006-2011. During her post-doctoral training, she worked on cell-based gain-of-function screening of microRNAs combined with reverse-phase protein arrays (RPPA). To date she has participated in several RNAi and cell-based functional screening projects in prostate and breast cancer. As a senior researcher at the Institute for Molecular Medicine Finland, FIMM, she has set-up comprehensive drug sensitivity profiling for patient-derived cells from prostate and renal cancer (Saeed et al., Eur Urol 2016). This work has been part of a large team science effort lined to the “Grand Challenge” on Individualized Systems Medicine that was initiated in leukemia (reviewed in Pemovska Drug Discovery 2015, Horvath et al., Nature Review Drug Discovery 2016). Since September 2016, Päivi Östling has a joint affiliation at FIMM and Science for Life Laboratory, the Department of Oncology and Pathology at the Karolinska Institutet, where her task is to set-up and develop drug sensitivity profiling as a co-Principal Investigator at the Olli Kallioniemi research group.
Christian is professor of clinical informatics at the university of Geneva and chairman of the division of medical information sciences at the university hospitals of Geneva. He is a medical doctor board certified in Internal Medicine with special emphasis on emergency medicine, master in public health from the University of Washington, parallel education in biomedical informatics at the University of Geneva, focusing on clinical information systems, clinical data interoperability and medical semantics. Christian played an important role in the Swiss Federal strategy for eHealth and the future federal law for the shared patient record as chair of the standard and architecture and semantics working groups. He is member of the executive board of the Swiss Personalized Health network initiative. One of the focus of his team is on phenotype clinical data interoperability and semantic representation to support research, including a strong lead on computational linguistics and tools to use medical narratives and texts. Christian co-authors more than 150 publications. He is editorial board member of several peer-reviewed journals in biomedical informatics, such as the Journal of the American Medical Informatics Association (JAMIA), PLOS One, Applied Clinical Informatics (ACI) and BMC Big Data Analytics. Christian was vice-chair of the board of directors of HIMSS until 2016. He is the president of the European federation of medical informatics. Christian has participated to several start-ups.
T. Oliver Chao, PhD. is a Head of Emerging Biomedical Sciences / Responsable Partenariats at Sanofi France. Dr. Chao has over 20 years of pharma experience, working closely with both industrial and academic partners. He has acquired extensive and in-depth knowledge from traditional drug discovery and therapeutic strategy to emerging sciences and exploratory biotechnology. By training, Dr. Chao is a biochemist/molecular biologist/neurochemist via University of Illinois, University of Chicago, and INSERM/College de France. He has been invited to organize and speak in many international conferences and symposiums. Dr. Chao resides in Paris, France, while he eats, dreams, and thinks globally.
Gordan Lauc is a Professor of Biochemistry and Molecular Biology at the University of Zagreb, Director of the National Centre of Research Excellence in Personalised Healthcare and Honorary Professor at the University of Edinburgh and Kings College London. He graduated molecular biology at the University of Zagreb in 1992, and obtained PhD in Biochemistry and the University of Zagreb in 1995. He got his postdoctoral training at the Institute for Medical Physics and Biophysics in Münster and Johns Hopkins University in Baltimore. Dr. Lauc is author of over 100 research papers and six international patents. His laboratory is a global leader in high-throughput glycomics. They performed the first large scale studies of the human plasma glycome (in 2009) and human IgG glycome (in 2011), which were the basis for the subsequent first GWAS of the human plasma and IgG glycomes. He is a currently president of the International Glycoscience Organization and member of the Steering Committee of the European Glycoscience Forum.
Helena is Director of Disruptive Technologies at Elsevier in Cambridge MA, where she makes use of big data and data science solutions to ease the translation of basic biology research insights into precision medicine actionability with a special focus and passion for the oncology problem space. Before that, she was Associate Director of Data Sciences at Foundation Medicine where she led a team of data scientists and engineers tasked with integration, management, standardization, reuse and analysis of the company’s knowledgebase (FoundationCORE). Helena has published more than 30 papers and received the 2013 Big Data award in the Semantic Web Challenge at the International Semantic Web Conference. Helena received her Ph.D. in Bioinformatics from the Universidade Nova de Lisboa.